Two cases of intestinal perforation in patients on anti-rheumatic treatment with etanercept [5]

Clinical and Experimental Rheumatology

Volumn 24, Issue 1, 2006, Pages 113-

  Corsi, Fabio ^b   Previde, P ^b   Colombo, F ^b   Cellerino, P ^b   Donati, M ^a   Trabucchi, E ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; PREDNISONE;

ABDOMINAL RADIOGRAPHY; ADULT; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DIVERTICULITIS; EMERGENCY SURGERY; GENERAL CONDITION DETERIORATION; HUMAN; INTESTINE DIVERTICULOSIS; INTESTINE PERFORATION; LETTER; LEUKOCYTOSIS; PATHOPHYSIOLOGY; PERITONITIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; INTESTINAL PERFORATION; MIDDLE AGED; PREDNISONE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 33645093179     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Safety Update on TNF-α Antagonists: Infliximab and Etanercept. http://www.fda.gov/ohrms/dockets/ac/Ol/briefing/ 3779b2-Ol-cber-safe-ty%20_revision2.pdf
2. MANADAN AM, BLOCK JA, SEQUEIRA W: Mycobacteria tubercolosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003; 21: 526.
3. MPOFU S, MPOFU CMA, HUTCHINSON D, MAIER AE, DODD SR, MOOTS RJ: Steroids, non-steroidal anti -inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004; 63: 588-90.
4. LAINE L, CONNORS LG et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 1 24: 288-92.
5. HUTCHINSON D, LYNCH M: Siginoid diverticular abscess perforation in 2 patients with rheumatoid arthritis treated with high dose corticosteroids. A cautionary tale. J Rheumatol 200 1; 28: 1935-6.
6. GALARIA NA, WERTH VP, SCHUMACHER HR: Leukocytoclastic vasculitis due to Etanercept. J Rheumatol 2000; 27: 2041-4.
7. ROBERTS L, McCOLL GJ: Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004; 34: 687-92.
8. MORRIS CR, HARVEY IM, STEBBINGS WSL, SPEAKMAN CTM, KENNEDY HJ: Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 2003; 90: 1267-72.
9. KAVANAUGH A, KEYSTONE EC: The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S203-S208.
10. MUELLER AR, PASCHER A, PLATZ KP et al.: Immuunosuppression following intestinal trasplantation. Transplant Proc 2004, 36: 325-8.
11. NANDA S, BATHON JM: Etanercept: a clinical review of current and emerging indications. Exp Opin Pharm 2004; 5: 1175-86.